Espicom publishes over 135 reports on companies developing anti-cancer drugs from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products.

For each company you can evaluate:
* Summary: At a glance review of agreements, products and R&D pipeline.
* Overview: Background, ownership structure and research techniques they have developed for drug discovery.
* Agreements: Key details of who the company is collaborating with, and on what.
* Product Portfolio: Product monographs, mechanism of action and indications approved and in development.
* R&D Pipeline: Concise summaries of products in research covering status, indication and clinical trials.
* Financials: An analysis of financial performance including P&L, R&D expenditure and funding. Incorporated in April 1988, Cell Genesys is focused on the development and commercialisation of novel biological therapies for patients with cancer. The company has multiple clinical stage product development programmes, a deep product pipeline in the cancer arena, an extensive patent portfolio and a strong financial position.

The company is conducting clinical trials in multiple types of cancer utilising two of its three product platform technologies: GVAX cancer vaccines and oncolytic virus therapies. Cell Genesys' cancer gene therapies, the company's third product platform, are being evaluated in preclinical programmes for multiple types of cancer.

Cell Genesys is developing a pipeline of cancer gene therapies. The company's lead preclinical programme focuses on the delivery of anti-angiogenesis genes.